- Home
- MA vs GILD Comparison
MA vs GILD Comparison
Compare MA & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MA | GILD |
|---|---|---|
| Founded | 1966 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.9B | 168.6B |
| IPO Year | 2005 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MA | GILD |
|---|---|---|
| Price | $489.98 | $125.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 18 |
| Target Price | ★ $649.19 | $148.39 |
| AVG Volume (30 Days) | 3.1M | ★ 6.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 0.66% | ★ 2.55% |
| EPS Growth | 18.93 | ★ 1684.21 |
| EPS | ★ 4.35 | 1.61 |
| Revenue | ★ $32,791,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $16.19 | $4.68 |
| Revenue Next Year | $12.35 | $6.04 |
| P/E Ratio | $111.88 | ★ $78.17 |
| Revenue Growth | ★ 16.42 | 9.98 |
| 52 Week Low | $464.52 | $107.19 |
| 52 Week High | $601.77 | $157.29 |
Technical Indicators
Market Signals| Indicator | MA | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 40.15 |
| Support Level | $487.11 | $116.55 |
| Resistance Level | $529.49 | $126.46 |
| Average True Range (ATR) | 9.78 | 3.58 |
| MACD | 0.42 | -0.57 |
| Stochastic Oscillator | 68.69 | 25.87 |
Price Performance
Historical ComparisonAbout MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).